Group 1 - The company,维立志博-B, plans to globally offer 32.0544 million shares, with 3.2055 million shares available in Hong Kong and 28.8489 million shares for international offering, along with an over-allotment option of 4.8081 million shares [1] - The subscription period is set from July 17 to July 22, with a maximum offer price of HKD 35.00 per share, and an entry fee of approximately HKD 3,535.30 for 100 shares [1] - The total expected fundraising amount is HKD 1.067 billion, with a net amount of HKD 968 million, which will be used for clinical development, enhancing preclinical assets, expanding existing pipelines, optimizing technology platforms, increasing production capacity, commercialization post-approval, and general corporate purposes [1] Group 2 - The company is a clinical-stage biotechnology firm focused on discovering, developing, and commercializing innovative therapies to address unmet medical needs in oncology, autoimmune diseases, and other significant conditions [1] - Specifically, the company is a leader in next-generation tumor immunotherapy, aiming to advance breakthrough cancer therapies to improve patient outcomes [1] Group 3 - For the fiscal years 2023, 2024, and the first quarter of 2025 ending March 31, the company's net profits were -362 million, -301 million, and -75.367 million respectively, with year-on-year changes of -29.01%, 16.85%, and 12.94% [2]
維立志博-B(09887.HK) 7月17日—7月22日招股